(Q40432628)

20 September 2017

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma (English)

1 reference

20 September 2017

phase II clinical trial

0 references

author name string

Jonathan E Rosenberg

1

1 reference

20 September 2017

Hans von der Maase

2

1 reference

20 September 2017

John D Seigne

3

1 reference

20 September 2017

Jozef Mardiak

4

1 reference

20 September 2017

David J Vaughn

5

1 reference

20 September 2017

Malcolm Moore

6

1 reference

20 September 2017

Deepak Sahasrabudhe

7

1 reference

20 September 2017

Peter A Palmer

8

1 reference

20 September 2017

Juan Jose Perez-Ruixo

9

1 reference

20 September 2017

Eric J Small

10

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

20 September 2017

1 reference

20 September 2017

103

1 reference

20 September 2017

10

1 reference

20 September 2017

2035-2041

1 reference

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

20 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

K-RAS mutation in transitional cell carcinoma of urinary bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Screening of H-ras gene point mutations in 50 cases of bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Optimal design for linear interpolation of curves.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

New drugs and new approaches for the treatment of metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21023

7 January 2021

Identifiers

DOI

10.1002/CNCR.21023

1 reference

20 September 2017

1 reference